192 completed, 22 unknown, 21 terminated, 17 recruiting. 279 Phase 3, 33 Phase 2.
Follow Type 2 Diabetes: new trials by email Literature Review of Type 2 Diabetes trials Research Report on Type 2 Diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both Zenagamtide, Semaglutide, Placebo - Type 2 Diabetes | Phase 3 | Not yet recruiting | Novo Nordisk A/S | 1200 | 2026-11-10 | 2026-11-12 |
| A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease Treated With Once Daily Basal Insulin Alone or in Combination With Metformin, SGLT2i, or Both Placebo, Zenagamtide - Type 2 Diabetes, Chronic Kidney Disease | Phase 3 | Not yet recruiting | Novo Nordisk A/S | 450 | 2026-11-10 | 2026-11-12 |
| Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes SHR-3167 Injection, Insulin glargine (IGlar) - Type 2 Diabetes | Phase 3 | Not yet recruiting | Jiangsu HengRui Medicine Co., Ltd. | 450 | 2026-11-01 | 2026-11-06 |
| A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes Petrelintide, Placebo - Obesity or Overweight, Type 2 Diabetes | Phase 3 | Recruiting | Hoffmann-La Roche | 600 | 2026-10-09 | 2026-11-05 |
| Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1） UBT251 Injection 2.0 mg, UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mg - Type 2 Diabetes | Phase 3 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 360 | 2026-09-07 | 2026-09-15 |
| Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) UBT251 Injection 2.0 mg group, UBT251 Injection 4.0 mg group, UBT251 Injection 6.0 mg group - Type 2 Diabetes | Phase 3 | Recruiting | The United Bio-Technology (Hengqin) Co., Ltd. | 956 | 2026-09-07 | 2026-09-14 |
| AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications Zenagamtide, Insulin glargine U-100 - Type 2 Diabetes, Cardiovascular Risk | Phase 3 | Recruiting | Novo Nordisk A/S | 1778 | 2026-08-24 | 2026-09-01 |
| A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar Placebo, Survodutide - Type 2 Diabetes | Phase 3 | Recruiting | Boehringer Ingelheim | 600 | 2026-08-24 | 2026-11-13 |
| Exercise and Intranasal Insulin in Type 2 Diabetes Intranasal Insulin, Intranasal Placebo, High Intensity Exercise - Type 2 Diabetes, Insulin Sensitivity/Resistance | Phase 2 / Phase 3 | Recruiting | Rutgers, The State University of New Jersey | 60 | 2026-08-03 | 2026-06-30 |
| Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients With Controlled Cancers Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes, China Import (dapagliflozin) + China Import (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes - Type 2 Diabetes | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | 600 | 2026-06-15 | 2026-08-27 |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight Cagrisema, Semaglutide - Obesity, Type 2 Diabetes | Phase 3 | Recruiting | Novo Nordisk A/S | 2500 | 2026-05-21 | 2026-09-30 |
| Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes QLG1091, Rybelsus - Type 2 Diabetes | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 478 | 2026-05-01 | 2026-04-28 |
| A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin HM11260C, Placebo - Type 2 Diabetes | Phase 3 | Recruiting | Hanmi Pharmaceutical Company Limited | 118 | 2026-04-13 | 2026-05-13 |
| A Study of HDM1005 in Participants With T2DM Not Controlled With Metformin Alone or in Combination With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor HDM1005 1, HDM1005 2, Mazdutide - Type 2 Diabetes | Phase 3 | Not yet recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 912 | 2026-03-27 | 2026-02-18 |
| A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone HDM1005 1, HDM1005 2, HDM1005 injection or placebo - Type 2 Diabetes | Phase 3 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 240 | 2026-02-24 | 2026-02-09 |
| A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) PF-08653944, Placebo - Obesity, Overweight and/or Obesity | Phase 3 | Active not recruiting | Pfizer | 1078 | 2026-02-24 | 2026-10-13 |
| A Research Study to See if Two Different Formulations of Oral Semaglutide Are Equally Safe and Effective in Reducing the Blood Sugar Level in Japanese People With Type 2 Diabetes Oral semaglutide - Type 2 Diabetes | Phase 3 | Completed | Novo Nordisk A/S | 267 | 2025-12-01 | 2026-08-13 |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide Cagrilintide, Placebo (matched to Cagrilintide) - Overweight, Obesity | Phase 3 | Active not recruiting | Novo Nordisk A/S | 330 | 2025-11-05 | 2026-10-07 |
| A Phase 3 Study of HS-20094 in Patients With T2DM HS-20094 Injection, Dulaglutide Injection - Type 2 Diabetes | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 546 | 2025-09-30 | 2025-09-05 |
| A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise Alone HS-20094 Injection, HS-20094 Placebo Injection - Type 2 Diabetes | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 204 | 2025-09-30 | 2025-09-05 |
Showing 20 of 279. Sign in to see all of them.
Diabetes Mellitus, Type 2 (279) · Diabetes Mellitus (44) · Obesity (25) · Insulin Resistance (11) · Overweight (11) · Metabolic Diseases (7) · Endocrine System Diseases (6) · Glucose Metabolism Disorders (6) · Hypertension (6) · Dyslipidemias (5) · Prediabetic State (5) · Cardiovascular Diseases (4) · Hyperlipidemias (4) · Renal Insufficiency, Chronic (4) · Kidney Diseases (3)
Nutritional and Metabolic Diseases (278) · Endocrine System Diseases (273) · Glucose Metabolism Disorders (273) · Metabolic Diseases (272) · Diabetes Mellitus (235) · Pathological Conditions, Signs and Symptoms (31) · Signs and Symptoms (26) · Body Weight (25) · Nutrition Disorders (25) · Overnutrition (25) · Overweight (15) · Hyperinsulinism (14) · Lipid Metabolism Disorders (12) · Female Urogenital Diseases and Pregnancy Complications (10) · Urogenital Diseases (10)
Metformin (43) · dapagliflozin (31) · Insulin Glargine (20) · saxagliptin (19) · Exenatide (16) · Sitagliptin Phosphate (14) · semaglutide (14) · Liraglutide (9) · orforglipron (9) · Pioglitazone (8) · Tirzepatide (8) · dulaglutide (7) · tesaglitazar (7) · Colesevelam Hydrochloride (6) · glimepiride (6)
AstraZeneca (49) · Eli Lilly and Company (28) · Novo Nordisk A/S (10) · Intarcia Therapeutics (7) · Daiichi Sankyo (6) · Jiangsu HengRui Medicine Co., Ltd. (6) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (5) · Mount Sinai Hospital, Canada (5) · Laboratorios Silanes S.A. de C.V. (4) · Merck Sharp & Dohme LLC (4) · Sanofi (4) · Chipscreen Biosciences, Ltd. (3) · Handok Inc. (3) · Innovent Biologics (Suzhou) Co. Ltd. (3) · Takeda (3)
United States (120) · China (60) · Mexico (56) · Canada (44) · Germany (36) · South Korea (35) · Poland (34) · India (33) · Puerto Rico (33) · Argentina (32) · Hungary (29) · Czechia (27) · Romania (26) · United Kingdom (26) · South Africa (25)
Deborah Price, MSc (6) · Ravi Retnakaran, MD (4) · Changyu Pan, M.D. (2) · Peter Ohman, MD (2) · Peter Ohman, MD, PhD (2)
PMID 38770818, PMID 26894924, PMID 38682786, PMID 27402391, PMID 33368935, PMID 39963952, PMID 41591636, PMID 22913891, PMID 27461213, PMID 29974618, PMID 35210595, PMID 18663165, PMID 18852398, PMID 25414932, PMID 25927357, PMID 29802530, PMID 29923298, PMID 30550345, PMID 31114694, PMID 31178433, PMID 31301210, PMID 31364269, PMID 31848983, PMID 33436401, PMID 34131047, PMID 34131048, PMID 34135015, PMID 34274407, PMID 36938582, PMID 37526908, PMID 37668888, PMID 37872654, PMID 39531161, PMID 40526444, PMID 41961454, PMID 42829184, PMID 16990155, PMID 17379048, PMID 17717285, PMID 17987126, PMID 18454655, PMID 18458145, PMID 18473688, PMID 18609080, PMID 18662495, PMID 18823658, PMID 18955637, PMID 19132850, PMID 19365563, PMID 19451554
2023 (4), 2025 (4), 2005 (2), 2015 (2), 2016 (2), 2019 (2), U01DK094406 (2), 1RC1DK086132 (1), 2014 (1), 2018 (1), R01DK029953 (1), R01DK076092 (1), R01DK088078 (1), R01DK089557 (1), R01DK126206 (1)